Track-and-trace requirements in Iowa 101
Iowa currently employs a mandated track-and-trace unique to the state and requires reporting of seed-to-sale activities for all licensed cannabis products.
In 2014, the legalization of CBD oil in Iowa began with Senate Bill 2360, which passed in the Senate and allowed for the possession and use of cannabidiol (CBD) with less than 3% THC for treating intractable epilepsy, under a neurologist's recommendation.
The Medical Cannabidiol Act was signed law in May 2014, effective January 2015, to allow children with intractable epilepsy to use CBD oil with a neurologist's recommendation. However, it did not provide a legal way to obtain the oil in Iowa.
In May 2017, the Medical Cannabidiol Act was signed into law. Iowa’s licensed dispensaries began providing medical cannabidiol products to patients on December 1, 2018. Iowa’s medical cannabidiol program authorizes the manufacture and sale of products that contain both CBD and THC. In other words, it is a program that allows for the legal manufacture and sale of medical cannabis products.
The Bureau of Cannabis Regulation at the Iowa Department of Health and Human Services is to have a high-quality, effective, and compliant medical cannabis program for Iowa residents with serious medical conditions.
